-
I-BET-762: BET Inhibitor Workflows for BRD4 Studies
2026-09-01
I-BET-762 is a high-affinity BET inhibitor for connecting transcriptional control with inflammation and ferroptosis. This practical guide shows how to build concentration-response experiments, combine BET inhibition with erastin, and troubleshoot ROS, FSP1, LPS-response, and viability readouts.
-
Annexin V-PE Reagent in CAR-T Cell Death Analysis
2026-09-01
Discover how the Annexin V-PE Reagent converts phosphatidylserine externalization into a decision-ready apoptosis readout for CAR-T research. This guide connects CD38 binder engineering with assay design, controls, and mechanistic interpretation.
-
Gramine, Ferroptosis, and the CUL3–MTDH Axis
2026-08-31
A 2026 study identifies Gramine as a selective inhibitor of triple-negative breast cancer models that acts through a previously underexplored CUL3–MTDH regulatory axis. By combining target-engagement assays, ferroptosis rescue experiments, genetic perturbation, and mouse models, the work connects CUL3 modulation with MTDH stabilization and ferroptotic tumor suppression.
-
Irisin Protects Mitochondria in Renal I/R Injury
2026-08-31
This study shows that the skeletal-muscle myokine irisin reduces renal ischemia–reperfusion injury while preserving mitochondrial organization and function in tubular epithelial cells. By combining patient associations, a mouse intervention model, tubular imaging, and mitochondrial pathway analysis, the work connects irisin signaling with PINK1–PARK2-associated mitochondrial quality control.
-
Cisplatin (CDDP): From DNA Damage to Assay Design
2026-08-30
Cisplatin (CDDP) is more than a cytotoxic benchmark: it is a tool for connecting DNA crosslinking, oxidative stress, apoptosis, and treatment resistance. This guide translates its mechanism and clinical context into better assay and xenograft-study decisions.
-
Pronase E Workflows for Ferroptosis Proteomics
2026-08-29
Pronase E is a broad-spectrum protease mixture for DARTS binding assays, peptide mapping, and controlled protein sample preparation. This practical guide connects its workflow advantages with mechanistic studies of gramine-induced ferroptosis in triple-negative breast cancer while emphasizing assay controls, reproducibility, and troubleshooting.
-
BAPTA-AM: Practical Calcium Chelation Guide
2026-08-28
BAPTA-AM is a cell-permeable calcium chelator for experimentally buffering intracellular Ca²⁺ and examining calcium-dependent phenotypes. It is suited to live-cell calcium, apoptosis, and signaling workflows, but requires solvent, magnesium-interference, optical, and potassium-channel controls; this dossier-based guide does not substitute for model-specific validation.
-
T-5224 for AP-1 Mechanism Studies
2026-08-28
T-5224 provides a selective way to test whether c-Fos/c-Jun AP-1 activity drives inflammatory, osteoclastogenic, or ferroptotic outputs. This practical guide combines arthritis-focused workflows with the reference study’s PI3K/AKT–ferroptosis findings to improve assay design, controls, and interpretation.
-
Gramine for Ferroptosis and TNBC Research
2026-08-27
Gramine is a mechanism-oriented tool for linking ferroptotic cell death with the CUL3–MTDH ubiquitination axis in triple-negative breast cancer models. This workflow translates reported target-validation findings into practical dose-response, rescue, biomarker, and troubleshooting strategies for cancer biology research.
-
NETosis and IL-36R Signaling in Psoriasis
2026-08-27
The reference study identifies coordinated TLR3 and P2X7R stimulation as a driver of neutrophil extracellular trap formation and links NET-associated inflammation to amplification through the IL-36/IL-36R axis. Its combination of ligand-based neutrophil experiments, an imiquimod-induced mouse model, primary keratinocytes, and Il1rl2 deficiency provides a mechanistic framework for studying NETosis as a modifiable component of psoriatic inflammation.
-
Iptacopan (LNP023) Complement Research Workflows
2026-08-26
Build more interpretable complement activation research with Iptacopan (LNP023), from factor B target engagement to C3 deposition and membrane attack complex readouts. This workflow guide connects complement-mediated hemolysis assays with translational disease models while emphasizing matrix control, orthogonal endpoints, and practical troubleshooting.
-
Nadolol (SQ-11725) Research Workflows
2026-08-26
Build cleaner cardiovascular experiments with Nadolol (SQ-11725), from beta-adrenergic pathway perturbation to transporter-aware exposure checks. This guide combines practical assay setup, comparative use cases, and lessons from a recent pharmacokinetic study without overstating cross-disease evidence.
-
Lisinopril Dihydrate: An Assay-First Guide
2026-08-25
Lisinopril dihydrate is a long-acting ACE inhibitor for mechanistic cardiovascular and renal research. This assay-first guide connects its renin–angiotensin system activity with peptidase counter-screening, formulation control, and model-specific interpretation.
-
Fingolimod (FTY720): Mechanism and Research Use
2026-08-25
Fingolimod (FTY720) is an orally bioavailable sphingosine-1-phosphate receptor modulator used clinically for relapsing multiple sclerosis. Its best-established action is lymphocyte egress inhibition, while BDNF and ERK1/2 findings support separate neurobiological research applications.
-
Gramine–CUL3–MTDH Ferroptosis in TNBC
2026-08-24
A 2026 reference study identifies Gramine as a mechanistically supported ferroptosis inducer in triple-negative breast cancer, acting through CUL3-mediated control of MTDH stability. Its combination of chemical-proteomic screening, target-engagement assays, genetic rescue, and mouse-model validation provides a framework for studying MTDH ubiquitination in cancer biology research.